Compare United Microelectronics Corp (UMC) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United Microelectronics Corp vs Zimmer Biomet Holdings Inc — how do they compare? United Microelectronics Corp trades at $22.96 (market cap $58.02B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: United Microelectronics Corp is far larger — about 3.4× Zimmer Biomet Holdings Inc's market cap, and United Microelectronics Corp pays the higher dividend (1.76%). Which is the better fit depends on your goals — on Pluang, investors hold United Microelectronics Corp for 42 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| UMC | ZBH | |
|---|---|---|
Market Cap | $58.02B | $16.95B |
Volume | 11,897,809 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $28.02 | $103.98 |
52-Week Low | $7.02 | $79.58 |
Typical Hold Time | 42 Days | 89 Days |
Enterprise Value | $55.10B | $24.02B |
Dividend Yield | 1.76% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UMC trades at $22.82, down 2.1% today but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals despite mixed moving averages, while fundamentals reveal robust profitability with 32.75% net income margin and improving cash flow trends. Recent news highlights analyst upgrades and strong AI-driven growth prospects.
Outlook remains positive with projected revenue growth to $250.7B in 2026 and intrinsic value estimates around $29 suggesting upside potential. Key risks include semiconductor cycle volatility and competitive pressures from larger foundries. Analyst consensus leans Hold but recent Strong Buy upgrades indicate growing optimism.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
